NCT02661373 - First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

March 9, 2018

Study Completion Date

March 9, 2018

Conditions

Malaria

Interventions

DRUG

SJ733

SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.

DRUG

Cobicistat

Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis